Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
This biotech stock looks like a great candidate to buy on the admittedly steep dip.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Malaysia’s central bank maintains key policy rate, says growth momentum to continue in 2027
Bank Negara Malaysia maintained its overnight policy rate at 2.75 per cent.
Steuer: Finanzamt fordert Steuer – obwohl der Erbe leer ausgeht
Selbst wenn ein Erbe erst spät von seinem Anspruch erfährt und leer ausgeht, fällt Erbschaftsteuer an. Der Bundesfinanzhof klärte, wieso das so ist – und welche Ausnahmen es gibt.
Chinese Refiners Pay Record Premiums for Russian ESPO Crude
Chinese refiners are paying a hefty premium for Russia’s ESPO crude to replace Iranian crude that independent refiners were importing before the U.S. installed its naval blockade on the country.
Nikkei Falls for Fourth Day as Stronger Yen and Rate Uncertainty Weigh
Tokyo stocks ended mixed on September 3, with the Nikkei 225 closing at 64,214.48, down 111.16 points, as uncertainty over interest rates and currencies kept pressure on risk assets, while the broader…
- Nikkei 225 fell 111.16 points, ending at 64,214.48 on September 3
- Stronger yen and rate hike expectations weighed on market sentiment
- Energy shares declined 3.26%, led by Inpex's 4% drop